Document resource
Objective The aim of this study was to conduct a survey of cardiac device implanting physicians to report utilisation trends, barriers and attitudes around the use of antibiotic envelope utilisation in the UK.Design An online survey devised by an implanting physician focus group, which included a mixture of multiple-choice and open text questions, was sent via email to UK-based physicians.Participants 500 implanting physicians across 159 sites in the UK, identified from the National Institute for Cardiovascular Outcomes Research Database.Results Responses were received from 117 participants (79% of whom were consultant cardiologists). The TYRX absorbable antibiotic envelope was most commonly used for device upgrades, compared with de novo pacemakers, cardiac resynchronisation therapy-pacemakers or -defibrillators (CRT-P/CRT-D) implants and generator replacements. A limited number (13%) of respondents used the PADIT (Prevention Of Arrhythmia Device Infection Trial) score to guide their use of TYRX while 31% of respondents were unaware of the score. Several risk factors (early pocket re-intervention, previous device infection and procedural duration) were reported as the most important factors in consideration of TYRX use; however, these are not included in the PADIT score. Key barriers to adoption included cost-effectiveness and lack of compelling clinical data and guidelines. Technical concerns were reported by 27% of respondents, translating into reduced utilisation in clinical practice.Conclusion This survey provides a snapshot of antibiotic envelope utilisation across device implanters in the UK. The PADIT score does not reflect the key decision-making factors reported by our surveyed cohort. There remains significant variation in patient selection and practical techniques as well as uncertainty surrounding the clinical evidence and cost-effectiveness of the TYRX envelope.